Orthovita to Present at the 2004 UBS Global Life Sciences Conference.MALVERN, Pa. -- Orthovita, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NM: VITA), a leading developer of orthopaedic biomaterials, announced today that it will participate as a presenting company at the 2004 UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference. Antony Koblish, President and Chief Executive Officer of Orthovita, is scheduled to present at 2:00 p.m. ET on Thursday, September 30, 2004, at the Grand Hyatt New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , located on Park Avenue at Grand Central Station in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . About the Company Orthovita is a leading biomaterials company with proprietary technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for restoration of the human skeleton. We develop and market novel synthetic-based biomaterial products for use in spine surgery, the repair of osteoporotic fractures, and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Scaffold technology platforms, which are designed to address the non-structural bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. market. Our longer-term clinical development program is focused on our CORTOSS(R) technology platform, which is designed for injections in osteoporotic spines to treat vertebral compression fractures vertebral compression fracture Compression fracture of back Orthopedics A traumatic fracture of a vertebral body which may occur in a background of osteoporosis or malignancy and cause kyphosis and spinal cord pressure. See Herniated disk. . Orthovita also pursues opportunities to work jointly with other leaders in biomaterials, such as Kensey Nash Corporation and Angiotech Pharmaceuticals, Inc. This press release may contain forward-looking statements regarding Orthovita's current expectations of future events that involve risks and uncertainties, including, without limitations, our products and other aspects of our business, as well as those listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. under the caption "Certain Risks Related to Our Business". Further information about these and other relevant risks and uncertainties may be found in Orthovita's filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion